Journals / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 6

The evaluation of hypermetabolic mediastinal?hilar lymph nodes determined byPET/CT in pulmonary and extrapulmonary malignancies: correlation with EBUS-TBNA

Pages
1234–1242
Publication Date
2015-12-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: When determining mediastinal-hilar lymph node metastasis via PET/CT, although a SUVmax cut-off value of 6.3 increases specificity and diagnostic accuracy, we think that a SUVmax cut-off value of 2.5 and above give more optimal results in routine practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: We aimed to define the optimal SUVmax cut-off value in determination of mediastinal-hilar lymph node metastasis, by comparing positive PET/CT results with the results of endobronchial ultrasound guided transbronchial needle aspiration biopsy (EBUS-TBNA).
📊
Key Findings & Data:Results: When a SUVmax value of 2.5 was used, the sensitivity, positive predictive value (PPV), and diagnostic accuracy of the PET/CT were 100%, 65.4%, and 65.4% respectively.
💡
Conclusion & Impact:Conclusion: When determining mediastinal-hilar lymph node metastasis via PET/CT, although a SUVmax cut-off value of 6.3 increases specificity and diagnostic accuracy, we think that a SUVmax cut-off value of 2.5 and above give more optimal results in routine practice.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:PET/CT · mediastinal?hilar lymph nodes · EBUS-TBNA

Abstract

Background/aim: We aimed to define the optimal SUVmax cut-off value in determination of mediastinal-hilar lymph node metastasis, by comparing positive PET/CT results with the results of endobronchial ultrasound guided transbronchial needle aspiration biopsy (EBUS-TBNA). Materials and methods: Thirty-one patients with malignancy whose PET/CT imaging revealed a hypermetabolic mediastinal and/or hilar lymph node and who had undergone EBUS-TBNA were evaluated retrospectively. Histopathology was regarded as the gold standard. The diagnostic role of PET/CT in mediastinal/hilar lymph node metastasis was investigated and compared with the results of contrast-enhanced CT. Results: When a SUVmax value of 2.5 was used, the sensitivity, positive predictive value (PPV), and diagnostic accuracy of the PET/CT were 100%, 65.4%, and 65.4% respectively. In the ROC analysis, the SUVmax cut-off value with the highest diagnostic accuracy (75%) was calculated as 6.3, and when this value was considered, the sensitivity, specificity, PPV, negative predictive value, and diagnostic accuracy of the PET/CT were determined as 70.6%, 83.3%, 88.9%, 60%, and 75% respectively (AUC: 0.779). The sensitivity, PPV, and diagnostic accuracy of the thorax CT were calculated as 91.1%, 72%, and 71.1%, respectively. Conclusion: When determining mediastinal-hilar lymph node metastasis via PET/CT, although a SUVmax cut-off value of 6.3 increases specificity and diagnostic accuracy, we think that a SUVmax cut-off value of 2.5 and above give more optimal results in routine practice.

Özet

Background/aim: We aimed to define the optimal SUVmax cut-off value in determination of mediastinal-hilar lymph node metastasis, by comparing positive PET/CT results with the results of endobronchial ultrasound guided transbronchial needle aspiration biopsy (EBUS-TBNA). Materials and methods: Thirty-one patients with malignancy whose PET/CT imaging revealed a hypermetabolic mediastinal and/or hilar lymph node and who had undergone EBUS-TBNA were evaluated retrospectively. Histopathology was regarded as the gold standard. The diagnostic role of PET/CT in mediastinal/hilar lymph node metastasis was investigated and compared with the results of contrast-enhanced CT. Results: When a SUVmax value of 2.5 was used, the sensitivity, positive predictive value (PPV), and diagnostic accuracy of the PET/CT were 100%, 65.4%, and 65.4% respectively. In the ROC analysis, the SUVmax cut-off value with the highest diagnostic accuracy (75%) was calculated as 6.3, and when this value was considered, the sensitivity, specificity, PPV, negative predictive value, and diagnostic accuracy of the PET/CT were determined as 70.6%, 83.3%, 88.9%, 60%, and 75% respectively (AUC: 0.779). The sensitivity, PPV, and diagnostic accuracy of the thorax CT were calculated as 91.1%, 72%, and 71.1%, respectively. Conclusion: When determining mediastinal-hilar lymph node metastasis via PET/CT, although a SUVmax cut-off value of 6.3 increases specificity and diagnostic accuracy, we think that a SUVmax cut-off value of 2.5 and above give more optimal results in routine practice.

🔖

Cite This Article

KANDEMİR, Z., ŞENTÜRK, A., ÖZDEMİR, E., YILDIRIM, N., HASANOĞLU, H. C., KESKİN, M., TÜRKÖLMEZ, Ş. (2015). The evaluation of hypermetabolic mediastinal?hilar lymph nodes determined byPET/CT in pulmonary and extrapulmonary malignancies: correlation with EBUS-TBNA. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 6, 1234–1242. https://ajindex.com/articles/113759

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer. Chest 2007; 132: 202–220.
  2. Gupta NC, Graber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small ( 3 cm) lymph node lesions. Chest 2000; 117: 773–778.
  3. Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR, Hopkins DM. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000; 70: 1154–1159.
  4. Rintoul RC, Skwarski KM, Murchison JT, Wallace WA, Walker WS, Penman ID. Endobronchial and endoscopic ultrasound- guided real time fine-needle aspiration for mediastinal staging. Eur Respir J 2005; 25: 416–421.
  5. Enön S, Tokat OA, Güngör A. Küçük hücreli dışı akciğer kanserinde nodal evrelemede invaziv prosedürlerin üstünlükleri. Tüberküloz ve Toraks 2005; 53: 401–406 (article in Turkish). Reed CE, Silvestri GA. Diagnosis and staging of lung cancer. In: Shields, TW, editor. General Thoracic Surgery. 6th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2005. pp. 1534–1547.
  6. Ravens-Fritscher A, Bohuslavizki KH, Brandt L, Bobrowski C, Lund C, Knofel WT, Pforte A. Mediastinal lymph node involvement in potentially resectable lung cancer. Chest 2003; 123: 442–451.
  7. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG- PET in the management of non-small cell lung cancer. Eur J Radiol 2003; 45: 49–59.
  8. Toloza EM, Harpole L, Detterbeck F, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123: 137–146.
  9. Dwamena BA, Sonnad SS, Angabaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213: 530–536.
  10. Gonzales-Stawinski GV, Lemaire A, Merchant F, O’Halloran E, Coleman RE, Harpole DH, D’Amico TA. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1900–1905.
  11. Pozo-Rodriguez F, Martin de Nicolas JL, Sanchez-Nistal MA, Maldonado A, Garcia de Barajas S, Calero-Garcia R, Pozo MA, Martin-Escribano P, Martin-Garcia I, Garcia-Lujan R, et al. Accuracy of helical computed tomography and (18 F) fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small cell lung cancer. J Clin Oncol 2005; 23: 8348–8356.
  12. Navani N, Nankivell M,